ニューヨークにおける胆道系癌の臨床試験
ニューヨーク内の拠点で、胆道系癌に関する15件の研究が参加者を募集しています。
ニューヨーク内の都市
公式研究テキスト（英語）
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Commack
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- Rosewell Park Comprehensive Cancer Center (Site 114), Buffalo
- Memorial Sloan Kettering Cancer Center (Site 108), New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Mineola
- Research Site, New York
- Research Site, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327), Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06428409Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Commack
被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/09/23更新 · NCT05489211Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Memorial Sloan Kettering Cancer Centers, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06282575Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, New York
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/09/04更新 · NCT07038343A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Roswell Park Comprehensive Cancer Center, Buffalo
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, White Plains
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/08/19更新 · NCT06467357A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1相
16歳以上 · 全性別 · 2026/06/02更新 · NCT07197554Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Roswell Park Comprehensive Cancer Center, Buffalo
- Montefiore Medical CenterMontefiore Medical Park, The Bronx
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/02更新 · NCT05733598Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/05更新 · NCT04900818ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。